NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Wall Street Analyst Weigh In
Separately, Piper Sandler reduced their price objective on shares of NextCure from $21.00 to $13.00 and set an "overweight" rating for the company in a research report on Monday, May 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, NextCure currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.
NextCure Price Performance
Shares of NASDAQ:NXTC opened at $4.71 on Monday. The stock's 50-day simple moving average is $4.50 and its two-hundred day simple moving average is $4.65. NextCure has a 52-week low of $3.25 and a 52-week high of $9.18.
NextCure (NASDAQ:NXTC - Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.06). Equities analysts anticipate that NextCure will post -2.69 earnings per share for the current year.